Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; complet ...
Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash ...
Even as investors, founders and shoppers alike pay close attention to better-for-you food innovation, the reality on shelves remains intense and uncertain. 2024 data shows that only about 29% of new ...
XPro™ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore ...
Australia’s medicine safety officials have warned the government they are flying blind on the use of puberty blocker drugs for gender-distressed minors.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
Fine Food Australia 2026 will see its first Sri Lanka Pavilion from August 31 to September 03, 2026, at Australia’s Melbourne Exhibition Centre. ..
ORLANDO, FL / ACCESS Newswire / February 13, 2026 / RedChip Companies will air interviews with Nexalin Technology, Inc.
Rare diseases affect only a small number of people yet have become an attractive target for ASX healthcare companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results